Thanks, makes sense.
Orilissa actually has it in its PI that it should only be used with non-hormonal contraceptives, which may be a serious limitation in this population (if physicians adhere). Patients start on OCs not just because they help with pain but also because they need contraception.
I think both in UF and Endo, there is a segment of physicians who is going to think that these are "bandaids" and the real solution is surgery (laparoscopy or hysterectomy), partly because that's how they make money. But the value proposition should appeal to patients (delay/prevent invasive treatments) and generalists who don't have a preference for surgeries. So, I agree, the opportunity is there for both indications, they just need to find the right patients and physicians. Going after the experts / specialists may not be the most optimal strategy (although it's typically the most efficient at launch). Broader / larger investment may be needed to unlock the opportunity for these drugs, and it'll likely take longer.
Market Data 
Markets 
AI
